44 results about "Cosmid" patented technology

The present invention is a method for the biosynthesis of hundreds of compounds, mainly found in the cannabis plant. The starting material for these compounds can be any biological compound that is used/produced in a biological organism from the sugar family starting materials or other low cost raw materials processed via enzymes or within organisms to give final products. These final products include, but are not limited to: cannabinoids, terpenoids, stilbenoids, flavonoids, phenolic amides, lignanamides, spermidine alkaloids, and phenylpropanoids. Specifically, the present invention relates to the regular/modified/synthetic gene(s) of select enzymes are processed and inserted into an expression system (vector, cosmid, BAC, YAC, phage, etc.) to produce modified hosts. The modified host is then optimized for efficient production and yield via manipulation, silencing, and amplifying inserted or other genes in the host, leading to an efficient system for product.

The invention relates to a novel beta glucosidase/xylosidase difunctional cellulose degradation enzyme RuGBGX2 as well as a coding gene and application thereof. The coding sequence of amino acid of the RuGBGX2 contains 18-755th sites of an SEQ ID NO 2 sequence. The RuGBGX2 is sourced from the rumen microorganism of yak from China, a novel coding gene of the beta glucosidase/xylosidase difunctional cellulose degradation enzyme RuGBGX2 is obtained by function screening and sequencing analysis on a rumen metagenome cosmid library and a subclone library. The beta glucosidase/xylosidase difunctional cellulose degradation enzyme provided by the invention can be widely applied to the degradation of cellulose and the fields such as cellulose biotransformation, chemical industry, spinning, foods, bioenergy, feed additives, medical industry and the like. By utilizing the difunctional enzyme RuGBGX2 to degrade wood fiber, the varieties of added enzymes can be reduced, and an enzymolysis process can be simplified.

The invention provides a recombinant duck enteritis virus (DEV) vaccine strain CCTCC NO:V201125 named rDEVus78Ha-Re6 for expressing an avian influenza virus haemagglutinin (HA) gene, and a constructing method and application thereof. The vaccine strain is prepared by the following steps of: inserting a genetic fragment SV40-HA comprising the avian influenza virus HA gene and an SV40 promoter sequence into a spacer between a US7 gene and a US8 gene of a DEV by adopting a recombinant cloning technology; constructing a cosmid for inserting an SV40-HA expression frame between the US7 gene and theUS8 gene; and saving to obtain the recombinant DEV vaccine strain CCTCC NO:V201125 for expressing the avian influenza virus HA gene. The invention further relates to a method for constructing the recombinant DEV vaccine strain and application of the recombinant DEV vaccine strain to preparation of a vaccine for preventing duck viral enteritis and avian influenza.

The present invention relates to the production and use of covalently closed circular (ccc) recombinant DNA molecules such as plasmids, cosmids, bacterial artificial chromosomes (BACs), bacteriophages, viral vectors and hybrids thereof, and more particularly to vector modifications that improve expression of said DNA molecules.

The invention discloses a Marek's disease virus (MDV) infectivity recombinant cloning system, and a construction method and application thereof and belongs to the field of biotechnologies. The MDV infectivity recombinant cloning system comprises a plurality of cosmids, wherein an MDV vaccine strain gene segment is cloned in each cosmid; the MDV vaccine strain gene segment contains mutually superposed regions and can be spliced to cover an integral MDV vaccine strain genome; an exogenous gene is inserted into a non-essential region for replication of at least one of the cosmids. The MDV infectivity recombinant cloning system can quickly and efficiently clone an exogenous gene expression cassette into the MDV genome to further realize rescue of the recombinant MDV. The recombinant cloning system can be used for very conveniently inserting different foreign genes into the corresponding regions so as to construct an MDV living-vector multi-vaccine.

The present invention relates to the expression and screening of genomic DNA sequences encoding uncharacterized genes and proteins. The present invention provides systems utilizing unique features of retroviral replication to analyze uncharacterized genes derived from genomic DNA samples. In preferred embodiments, a segment of genomic DNA is inserted between 5′ and 3′ viral long terminal repeats (LTRs) in a vector (e.g., a plasmid, cosmid, or artificial chromosome vector). The resulting vector (or library of vectors containing a plurality of independent genomic sequences) is then introduced into a retroviral packaging cell. The resulting provirus or proteins expression from the provirus are then analyzed.

The present invention relates to the propagation of covalently closed circular recombinant DNA molecules such as plasmids, cosmids, bacterial artificial chromosomes (BACs), bacteriophages, viral vectors and hybrids thereof, and more particularly is strain modifications that improve strain viability, plasmid stability, plasmid production yield, and plasmid-directed protein production yield, using said DNA molecules in fermentation culture.

The invention provides a recombinant duck viral enteritis virus vaccine for expressing secretory duck Tembusu virus M/E protein, and a construction method and application thereof. The collection number is CCTCC NO:V201215, and the name is rDEV-TME-tPAS. By using a recombinant clone technique, a gene segment rDEV-TME-tPAS comprising an SV40 promoter, duck Tembusu virus M and E proteins and a tPA (Tissue plasminogen activator) signal peptide sequence is inserted into a spacer between the US7 and US8 genes of the duck viral enteritis virus to construct a cosmid in which the rDEV-TME-tPAS expression frame is inserted between the US7 and US8 genes, thereby obtaining the recombinant duck viral enteritis virus vaccine CCTCC V201215 for expressing secretory duck Tembusu virus M/E protein. The invention also provides a method for constructing a recombinant duck viral enteritis virus vaccine strain and application of the recombinant duck viral enteritis virus vaccine strain in preparing a vaccine for preventing infectious diseases caused by duck viral enteritis virus and duck Tembusu virus.

The invention belongs to the field of biological engineering, and relates to a novel endoglucanase RuCelB, a coded gene, a preparation method and an application thereof. The RuCelB contains a 25th-336th amino acid residue sequence of SEQ ID NO.2. The preparation method is as follows: obtaining positive cloning capable of hydrolyzing sodium carboxymethylcellulose by active screening rumen microorganism metagenomic cosmid library of a yak, and further obtaining a whole-length cds sequence of the RuCelB by building subcloning, sequencing and homologous comparison; and carrying out recombined expression and obtaining the RuCelB. The specific activity of the RuCelB taking the sodium carboxymethylcellulose as a substrate is up to 158.8U/mg, and the RuCelB also has the degradability for the substrates such as filter paper, cellotriose and the like. The RuCelB can be widely applied in degradation of cellulose, comprising the industries such as cellulose biotransformation, chemical engineering, textile, food, bioenergy, feedstuff adding, pharmaceutical Industry and the like.

The invention provides a recombinant duck viral enteritis virus vaccine for expressing secretory duck Tembusu virus E protein, and a construction method and application thereof. The collection number is CCTCC V201214, and the name is rDEV-TE-tPAS. By using a recombinant clone technique, a gene segment SV40-E-tPA comprising an SV40 promoter, a duck Tembusu virus E protein and a tPA (Tissue plasminogen activator) signal peptide sequence is inserted into a spacer between the US7 and US8 genes of the duck viral enteritis virus to construct a cosmid in which the SV40-E-tPA expression frame is inserted between the US7 and US8 genes, thereby obtaining the recombinant duck viral enteritis virus vaccine CCTCC V201214 for expressing secretory duck Tembusu virus E protein. The invention also provides a method for constructing a recombinant duck viral enteritis virus vaccine strain and application of the recombinant duck viral enteritis virus vaccine strain in preparing a vaccine for preventing infectious diseases caused by duck viral enteritis virus and duck Tembusu virus.

The invention discloses an additive for directly reducing nickel laterite ores, which is mainly prepared from an NCS additive, sodium sulfate, calcium carbonate, sodium phosphate, soda ash and borax respectively according to proportions of 15 to 25 percent, 5 to 10 percent, 2 to 10 percent, 1 to 5 percent and 2 to 5 percent of mass of the nickel laterite ores. The invention also discloses a method for preparing ferro-nickel alloy powder by the additive. The NCS of the additive is in contact with water in the nickel laterite ores to release more Ca and Al high valence cations and the Ca and Al high valence cations neutralize negative charges of cosmid, so that a diffusion layer is thinned and an enrichment effect of ferro-nickel is improved. In the reducing process, the additive reacts with the nickel laterite ores and breaks the structure of the nickel laterite ores, and a high-enrichment ferro-nickel element is obtained. Compared with other additives, the additive not only has low cost and is environmental-friendly, but also cannot corrode equipment and has wide market popularization prospect.

The invention discloses a recombined chicken Marek's disease virus vaccine strain for expressing Gag and Env genes of an avian leukosis virus subgroup J (ALV-J) and a construction method and application of the recombined chicken Marek's disease virus vaccine strain, and belongs to the technical field of medicine or veterinary medicine. By means of the recombination and clone technology, a gene segment CAG-ALVGE containing the ALV-J Gag and Env genes and a CAG promoter sequence is inserted in a US2 gene of the strain 814 of the chicken Marek's disease virus, a recombined cosmid with a CAG-ALVGE expression frame inserted in a US2 gene is constructed, and the recombined chicken Marek's disease virus vaccine strain for expressing the Gag and Env genes is obtained through salvation of the recombined cosmid. Research shows that the obtained vaccine strain has the same in-vitro replication ability as a parent virulent vaccine strain 814 and good hereditary stability, and can resist attacks of a very virulent MDV strain and a very virulent ALV-J strain at the same time. It can be seen that the obtained recombined MDV vaccine strain can be used for preparing medicine for preventing or treating avian leukosis and the chicken Marek's disease.

The present invention relates to novel genes located in two chromosomal regions within uropathogenic E. coli that are associated with virulence. These chromosomal regions are known as pathogenicity islands (PAIs). In particular, the present application discloses 142 sequenced fragments (contigs) of DNA from two pools of cosmids covering pathogenicity islands PAI IV and PAI V located on the chromosome of the uropathogenic Escherichia coli J96. Further disclosed are 351 predicted protein-coding open reading frames within the sequenced fragments.

Methods of inducing immune responses in individuals against a pathogen are disclosed. Methods of treating individuals susceptible to or suffering from a disease associated with a genetic defect which results in the non-production or under production of a protein or the production of a non-functioning or partially functioning protein are disclosed. Methods of delivering a protein to an individual are disclosed. Pharmaceutical compositions that comprise cosmids are disclosed.